DDInter1133 DDInter1376
A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Mechlorethamine {u} (Compound) resembles {v} (Compound) Cyclophosphamide
Mechlorethamine {u} (Compound) treats {v} (Disease) hematologic cancer
Mechlorethamine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Mechlorethamine {u} (Compound) causes {v} (Side Effect) Thrombosis
Mechlorethamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Mechlorethamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Mechlorethamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Mechlorethamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Mechlorethamine {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Mechlorethamine {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Mechlorethamine (Compound) resembles Cyclophosphamide (Compound)
Mechlorethamine (Compound) treats hematologic cancer (Disease)
Mechlorethamine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Mechlorethamine (Compound) causes Thrombosis (Side Effect)
Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Warfarin
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Mechlorethamine may lead to a major life threatening interaction when taken with Clozapine
Mechlorethamine may lead to a major life threatening interaction when taken with Leflunomide